Langsung ke konten utama

Postingan

IMS Health Forecasts 4.5% To 5.5% Growth For Global Pharmaceutical Market in 2009, Exceeding $820 Billion

(BUSINESS WIRE)--The global pharmaceutical market is expected to grow 4.5 - 5.5 percent next year, a pace similar to 2008, according to the IMS Global Pharmaceutical and Therapy Forecast™ released today by IMS Health (NYSE: RX). The forecast, the leading annual industry indicator of market dynamics and therapy performance, predicts global pharmaceutical sales to surpass $820 billion in 2009, reflecting sustained double-digit growth in key emerging countries tempered by a slower pace in more established markets. This includes the U.S., where growth is expected to be in the 1 - 2 percent range for both 2008 and 2009. "In many respects, 2009 will reflect the new shape of the global pharmaceutical market, the result of market factors that have gained momentum over the past several years," said Murray Aitken, senior vice president, Healthcare Insight, IMS. "Pharmaceutical growth next year will hold steady at 2008 levels. The market will continue to contend with a number of fo...

FDA Approves Toviaz, a New Drug to Treat Overactive Bladder

The U.S. Food and Drug Administration has approved a new drug to help patients suffering from overactive bladder (OAB). Toviaz (fesoterodine fumarate) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence (leakage of urine), that are characteristic symptoms of OAB. "Patients who suffer from overactive bladder face quality of life issues that can hamper their ability to enjoy life to its fullest," said George Benson, M.D., deputy director, Division of Reproductive and Urologic Products at the FDA’s Center for Drug Evaluation and Research. "This new drug will provide an additional treatment option to help them manage problems with an overactive bladder." Toviaz will be available by prescription only, as an extended release tablet in either 4 mg or 8 mg dosage strengths. It is to be administered once daily. The recommended starting dose is 4 mg, which can be increased to 8 mg if ...

Sanofi-Aventis menarik obat anti-obesitas dari pasaran di Eropa

Pihak berwenang Uni Eropa menangguhkan penjualan anti-obesitas Acomplia milik farmasi raksasa Sanofi-Aventis di seluruh Uni Eropa, walaupun belum dilakukan di seluruh dunia. "Penjualan telah dihentikan di semua apotik di 18 negara Uni Eropa di mana obat disalurkan," menurut juru bicara Sanofi-Aventis kepada AFP. Sanofi-Aventis mengatakan Badan Pengawasan Obat Eropa (EMEA) telah memperingatkan bahwa pasien yang menggunakan obat hampir dua kali lipat berisiko masalah kejiwaan."Risiko penggunaan Acomplia sekarang lebih besar dari manfaat yang diterima pasien sesuai dengan pedoman terkini," menurut badan EMEA. Eropa telah mengizinkan penjualan Acomplia sejak 2006, tetapi belum resmi beredar di Amerika Serikat di mana pihak berwenang Amerika (FDA) yakin obat ini mendorong pikiran bunuh diri, walaupun pada pasien tanpa sejarah depresi. Perusahaan menyatakan tidak ada perintah penarikan obat di 14 negara non-Uni Eropa di mana Acomplia dijual. Para pengguna Acomplia...

Is Your Blog Worthy of a $10,000 Scholarship?

Apakah kamu ngeblog dan rencana kuliah di Amerika ? Apakah kamu mau $10.000 untuk biaya buku, uang kuliah dan biaya hidpu lainnya ? Kalau iya, baca selanjutnya. Tahun ini The Blogging Scholarship memberikan $10.000 bagi mahasiswa yang ngeblog (bukan goblog yach). Para juri akan memilih 10 finalis. Pemilihan melalui voting pada publik tanggal 3-17 November 2008. Pendaftarannya ditutup tanggal 30 Oktober 2008. Ayo buruan ! Informasi persyaratan beasiswa, kunjungi situs The Blogging Scholarship .

About blogging via email

Eureka ! Trying something new about blogging ...I hope it's work Wah senangnya hari ini bisa lihat postingan yang aku kirim via email...Maklum newbie dalam hal blogging. Tadinya mau pake Twitter tapi tetap tidak bisa diakses dari kantor. Semua yang berbau social networking dilarang alias diblok di server. Tapi syukur deh sudah bisa ketemu cara yang lebih mudah 'berkicau' selain pake twitter . Cara ini saya temukan di blog Ivan Lanin sang wikipediawan . kalau ada yang mau coba silahkan klik disini . Nofa Posted by email from nofa's posterous

Inilah Finalis RISTEK-KALBE SCIENCE AWARD 2008

Setelah melalui proses penjurian yang cukup ketat, akhirnya muncul para finalis RISTEK-KALBE SCIENCE AWARD 2008 seperti tercantum dalam situs resminya tgl 17 Oktober 2008. 10 Finalist Best Research Akhmad Kharis Nugroho, M.Si., Apt - Bagian Farmasetika Fakultas Farmasi UGM Agus Zainal Arifin, S.Kom., M.Kom - Institut Teknologi Sepuluh November, Surabaya Arief Budi Witarto - Puslit Bioteknologi LIPI Cibinong Heni Rachmawati, Apt., M.Si - Sekolah Farmasi ITB Khie Khiong, S.Si., M.Si., M.Pharm. Sc., Ph.D - Divisi Imunologi Puslit Ilmu Kedokteran (PPIK), FK Maranatha Maggy Thenawidjaja Suhartono, Prof. - Institut Pertanian Bogor Maria Immaculata Iwo, M.Si., Apt. - Sekolah Farmasi ITB Ronny Martien, Dr.rer.nat., M.Si - Fakultas Farmasi, Universitas Gadjah Mada Sukmadjaja Asyarie, Dr. - Sekolah Farmasi ITB Sunu Budhi Rahardjo, dr. Ph. D - Divisi Litbang PJN Harapan Kita 5 Finalist Young Scientist Akhmad Kharis Nugroho Dr., M.Si Apt. - Fakultas Farmasi UGM Heni Rachmawati, Dr. Apt., M.S...

Paracetamol Use in Infancy and Risk of Asthma in Children Aged 6 to 7 Years

Buat para dokter dan apoteker , berikut ini ada informasi terbaru mengenai kaitan penggunaan obat parasetamol dengan peningkatan risiko gejala konjungtivitis hidung dan eksim pada anak-anak. Untuk para orangtua, agar lebih memperhatikan penggunaan obat ini dan senantiasa mengkonsultasikan penggunaannya dengan apoteker dan dokter nya. The reported use of paracetamol (acetaminophen) in the first year of life is associated with increases in reported symptoms of asthma and risk of severe asthma symptoms in children aged 6 to 7 years, according to analysis of data from the multicentre, multicountry, cross-sectional International Study of Asthma and Allergies in Children (ISAAC). The study also found an association between use of paracetamol in childhood and an increased risk of symptoms of rhinoconjunctivitis and eczema in childhood, said principal investigator Richard Beasley, MD, Medical Research Institute of New Zealand, Wellington, New Zealand. The increased international use...